BioVie (BIVI) Stock Price, News & Analysis

Company Overview

BioVie Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease. BIV201 is being assessed for its potential to reduce ammonia levels and improve cognitive function, with data from early studies indicating a favorable safety profile and signs of clinical benefit.

In addition to its lead program, BioVie maintains exploratory efforts targeting other chronic liver indications, including primary biliary cholangitis and alcohol‐associated liver disease. These preclinical and early‐stage candidates leverage the company’s expertise in small‐molecule modulation of metabolic and inflammatory pathways, with the goal of expanding treatment options for patients who currently have limited therapeutic choices.

Headquartered in Emeryville, California, BioVie was founded with the mission of transforming the management of liver diseases through innovative drug development. The company operates in collaboration with leading academic institutions and clinical research organizations across the United States and Canada. Guided by an experienced executive team with backgrounds in biotechnology and pharmaceutical development, BioVie is committed to advancing its portfolio toward late‐stage clinical trials and eventual regulatory approval.

Key Stats

• Today's Range: $2.00 to $2.22
• 50-Day Range: $0.96 to $2.27
• 52-Week Range: $0.82 to $3.79
• Volume: 699,316 shs
• Average Volume: 13.98 million shs
• Market Capitalization: $18.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

BioVie Stock Analysis - MarketRank™

BioVie scored higher than 4% of companies evaluated by MarketBeat, and ranked 907th out of 920 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

BioVie has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

BioVie has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioVie is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioVie is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioVie has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.98% of the float of BioVie has been sold short.

Short Interest Ratio / Days to Cover

BioVie has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioVie has recently increased by 56.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioVie does not currently pay a dividend.

Dividend Growth

BioVie does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.43

News Sentiment

BioVie has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for BioVie this week, compared to 2 articles on an average week.

Search Interest

9 people have searched for BIVI on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioVie insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.90% of the stock of BioVie is held by insiders.

Percentage Held by Institutions

4.59% of the stock of BioVie is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 8/28/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BIVI
• CIK: 1580149
• Web: bioviepharma.com
• Phone: (775) 888-3162
• Fax: N/A
• Employees: 10
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($3.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -126.02%
• Return on Assets: -108.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.59
• Quick Ratio: 3.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.22 per share
• Price / Book: 1.80

Miscellaneous

• Outstanding Shares: 8,450,000
• Free Float: 8,375,000
• Market Cap: $18.51 million
• Optionable: No Data
• Beta: 0.60